FDA approves new injection for HIV prevention

The American Food and Drug Administration approved an HIV prevention medication that has been very effective in clinical studies.

Lenacapavir is an injectable treatment that is given twice a year to prevent HIV infection in adults and adolescents. In their announcement of 17 June with regard to the FDA approval, Gilead Sciences, the medicine manufacturer, stated that it will be brought to the market Under the brand name Yeztugo.

“This is a historic day in the decades long fight against HIV. Yeztugo is one of the most important scientific breakthroughs of our time and offers a very real opportunity to put an end to the HIV epidemic,” said Daniel O’day, chairman and Chief Executive Officer of Gilead Sciences, in a statement. “This is a medicine that only needs to be given twice a year and has demonstrated remarkable results in clinical studies, which means that HIV prevention could transform. Gilead scientists have made their life’s work to end HIV, and now, with the FDA approval of Yeztugo and in collaboration with our many partners, we can help.”

Lenacapavir is a captide inhibitor, an antiviral medication that focuses on the HIV “capside”, a protein scale that protects the genetic material and enzymes of the virus. Last year, the drug turned out to be almost 100% effective in preventing HIV in large studies. This could possibly interrupt the transfer of the virus that infects around 1.3 million people worldwide every year.

The company states that it intends To launch the drug quickly in the US And requires approval in countries that depend on the FDA regulations for authorization, including Argentina, Mexico and Peru. The company also applied for legal approval from Lenacapavir in Australia, Brazil, Canada and South Africa.

Moreover, Gilead works closely with insurers and caregivers established in the US to guarantee the coverage for the medicine. Via the Advancing Access® Co-Pay Savings program, the company will lower out-of-pocket costs for uninsured patients. Visit the Gilead website To learn more About Lenacapavir.

Related content: FDA plans to limit COVID vaccine to the elderly and the high risk